Shelf life (days): 1460.0
Formulation: A crystalline solid
Formal Name: N-[3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]-cyclopropanesulfonamide
Purity: ≥95%
Formula Markup: C19H20F3IN2O5S
Formula Weight: 572.3
CAS Number: 923032-37-5
Notes: Refametinib is an allosteric, selective inhibitor of MEK1 and MEK2 (IC50s = 19 and 47 nM, respectively).{27937} It blocks phosphorylation of ERK1/2 across several human cancer cell lines differing in tissue origin and BRAF mutational status (EC50s = 2.5-16 nM), inhibiting cell cycling in cancer cells but not in primary cells.{27937} Refametinib is orally available and active in human tumor xenograft models.{27937} It has potential utility, particularly in combination therapy, in certain forms of cancer.{27939,27938,27940}